Non-invasive Assessment of Liver Fibrosis
Chronic liver disease due to a variety of etiologies is a leading cause of morbidity and mortality in the US. Regardless of etiology, assessing the stage of liver disease is critical for treatment decisions, prognosis and general medical management. The gold standard for assessing liver fibrosis is a biopsy. However, biopsies are invasive, expensive and can be accompanied by a number of complications. For these reasons, many non-invasive markers (NIMs) have been developed and are increasingly used in clinical practice. This presentation will review non-invasive approaches for assessing liver fibrosis, with an emphasis on surrogate serum biomarkers, including Fibrosure and Fibrometer.
Originally presented on April 30, 2015 in Salt Lake City, Utah.
Patricia R. Slev, PhD
Medical Director, Serological Hepatitis/Retrovirus Laboratory, ARUP Laboratories
Co-Medical Director, Immunogenetics, ARUP Laboratories
Associate Professor of Pathology, University of Utah School of Medicine
Dr. Slev is the medical director of the Serological Hepatitis/Retrovirus Laboratory and co-medical director of Immunogenetics at ARUP, and an assistant professor of pathology at the University of Utah School of Medicine. Dr. Slev earned her PhD in immunology and laboratory medicine from the University of Florida, Gainesville and completed a fellowship in clinical chemistry at the University of Utah. She is board certified by the American Board of Clinical Chemistry. Dr. Slev’s research interests are in immunogenetics and pathogen interactions, particularly HIV and viral hepatitis.
After this presentation, participants will be able to:
- Explain pathogenesis of liver fibrosis.
- Explain the advantages and limitations of non-invasive markers for assessing liver fibrosis.
- Describe common serum marker assays for assessing liver fibrosis.
University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories